Buckley LA - Search Results

1

Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.

Buckley LA, Chapman K, Burns-Naas LA, Todd MD, Martin PL, Lansita JA. Buckley LA, et al. Int J Toxicol. 2011 Oct;30(5):583-90. doi: 10.1177/1091581811415875. Int J Toxicol. 2011. PMID: 22013138 Review.

2

Biologically-based models of dioxin pharmacokinetics.

Buckley LA. Buckley LA. Toxicology. 1995 Sep 1;102(1-2):125-31. doi: 10.1016/0300-483x(95)03041-d. Toxicology. 1995. PMID: 7482547 Review.

3

Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.

Buckley LA, Benson K, Davis-Bruno K, Dempster M, Finch GL, Harlow P, Haggerty HG, Hart T, Kinter L, Leighton JK, McNulty J, Roskos L, Saber H, Stauber A, Tabrizi M. Buckley LA, et al. Int J Toxicol. 2008 Jul-Aug;27(4):303-12. doi: 10.1080/10915810802367016. Int J Toxicol. 2008. PMID: 18821393

4

High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.

Buckley LA, Dorato MA. Buckley LA, et al. Regul Toxicol Pharmacol. 2009 Aug;54(3):301-7. doi: 10.1016/j.yrtph.2009.05.015. Epub 2009 May 27. Regul Toxicol Pharmacol. 2009. PMID: 19477212

5

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates.

Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, Green C, Ragan I, Robinson V. Chapman K, et al. MAbs. 2009 Sep-Oct;1(5):505-16. doi: 10.4161/mabs.1.5.9676. Epub 2009 Sep 30. MAbs. 2009. PMID: 20065651 Free PMC article.

6

The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates.

Chapman KL, Andrews L, Bajramovic JJ, Baldrick P, Black LE, Bowman CJ, Buckley LA, Coney LA, Couch J, Maggie Dempster A, de Haan L, Jones K, Pullen N, de Boer AS, Sims J, Ian Ragan C. Chapman KL, et al. Among authors: buckley la. Regul Toxicol Pharmacol. 2012 Mar;62(2):347-54. doi: 10.1016/j.yrtph.2011.10.016. Epub 2011 Nov 6. Regul Toxicol Pharmacol. 2012. PMID: 22100994

7

Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.

Buckley LA, Sanbuissho A, Starling JJ, Knadler MP, Iversen PW, Jakubowski JA. Buckley LA, et al. Int J Toxicol. 2012 Jul-Aug;31(4):317-25. doi: 10.1177/1091581812445073. Epub 2012 Jun 12. Int J Toxicol. 2012. PMID: 22692976

8

Toxicology testing in drug discovery and development.

Dorato MA, Buckley LA. Dorato MA, et al. Among authors: buckley la. Curr Protoc Toxicol. 2007 Feb;Chapter 19:Unit19.1. doi: 10.1002/0471141755.tx1901s31. Curr Protoc Toxicol. 2007. PMID: 23045141

9

Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients.

Buckley LA, Salunke S, Thompson K, Baer G, Fegley D, Turner MA. Buckley LA, et al. Int J Pharm. 2018 Feb 5;536(2):563-569. doi: 10.1016/j.ijpharm.2017.07.042. Epub 2017 Jul 17. Int J Pharm. 2018. PMID: 28729174 Free PMC article.

10

Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership Group.

Birkebak J, Buckley LA, Dambach D, Musvasva E, Price K, Ralston S, Sacaan A. Birkebak J, et al. Among authors: buckley la. Regul Toxicol Pharmacol. 2019 Mar;102:40-46. doi: 10.1016/j.yrtph.2018.12.012. Epub 2018 Dec 19. Regul Toxicol Pharmacol. 2019. PMID: 30576687 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page